Abstract:

General tendency in the pharmaceutical industry is to use either a chiral substrates or to perform chiral separations to obtain only one specific isomer as an active principle in order to decrease a metabolic load in patient´s organism. Tenofovir 1 is an active principle of the Viraed® and is liberated from its prodrug form. Viraed® is approved for treatment of HIV and HBV infections as an inhibitor of reversed transcriptase. One of the components of Tenofovir is (R)- 1,2-propanediol 2. Reported here are initial stages of obtention of (R) 2 and its enantiomer (S) 2 via desymmetrization of easily available glycerol and racemic 1,2-propanediol.